Last reviewed · How we verify

Biological analysis — Competitive Intelligence Brief

Biological analysis (Biological analysis) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immune checkpoint inhibitor. Area: Oncology.

phase 2 Immune checkpoint inhibitor PD-1 Oncology Biologic Live · refreshed every 30 min

Target snapshot

Biological analysis (Biological analysis) — Hospices Civils de Lyon. This drug targets the PD-1 receptor to modulate the immune response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Biological analysis TARGET Biological analysis Hospices Civils de Lyon phase 2 Immune checkpoint inhibitor PD-1
Penpulimab kcqx PENPULIMAB Akeso Biopharma marketed Pd-1 2025-01-01
Tevimbra TISLELIZUMAB Beigene marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 2025-01-01
Loqtorzi TORIPALIMAB Coherus Biosciences Inc marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 2024-01-01
Unloxcyt COSIBELIMAB Checkpoint Therapeutics Inc marketed Programmed Death Ligand-1 Blocker [EPC] Pd-1 2024-01-01
Jemperli DOSTARLIMAB GSK marketed Programmed Death Receptor-1 Blocking Antibody [EPC] PD-1 2021-01-01
Libtayo CEMIPLIMAB Regeneron Pharmaceuticals marketed PD-1 2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immune checkpoint inhibitor class)

  1. Sun Pharma Advanced Research Company Limited · 2 drugs in this class
  2. Brenda Cooper, MD · 1 drug in this class
  3. Grace Therapeutics Inc. · 1 drug in this class
  4. EMS · 1 drug in this class
  5. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
  6. Glycotope GmbH · 1 drug in this class
  7. Bristol-Myers Squibb · 1 drug in this class
  8. HK inno.N Corporation · 1 drug in this class
  9. Hanlim Pharm. Co., Ltd. · 1 drug in this class
  10. Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Biological analysis — Competitive Intelligence Brief. https://druglandscape.com/ci/biological-analysis. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: